![Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile](https://i1.rgstatic.net/ii/profile.image/1001884793991170-1615879357772_Q512/Michael-Gonzalez-24.jpg)
Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/eab7d797-1589-4839-acaa-71c8caa14f38/15ff2.jpg)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in
![PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial](https://i1.rgstatic.net/publication/335550663_Ticagrelor_in_patients_with_diabetes_and_stable_coronary_artery_disease_with_a_history_of_previous_percutaneous_coronary_intervention_THEMIS-PCI_a_phase_3_placebo-controlled_randomised_trial/links/5dab261aa6fdccc99d91d5b6/largepreview.png)
PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
![How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate](https://i1.rgstatic.net/ii/profile.image/375942640881665-1466643118917_Q512/Hannah-Kirkwood-2.jpg)
How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate
![Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry - eClinicalMedicine Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry - eClinicalMedicine](https://www.thelancet.com/cms/attachment/baf97996-e6e0-44da-adaf-4042c395756d/gr1_lrg.jpg)
Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry - eClinicalMedicine
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/08339483-5351-49f4-9caf-45ba5014d108/15ff1b.jpg)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/0f7b0cea-8b0f-4c9a-bebf-7c70c3d1d072/15ff1a.jpg)